NEDD9 and breast carcinoma: found that NEDD9 overexpression inhibited HDAC4 activity to enhance H3K9 acetylation of the Nedd9 promoter and activation of the FAK/NF-κB signaling pathway, leading to promote IL-6 secretion, which further drives breast cancer progression.